stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) EV/FCF
As of 6 November 2026, Travere Therapeutics, Inc. (TVTX) trades at a EV/FCF of 56.8×. Over the past ten years it has ranged from −185× (June 2026) to 444× (August 2026); the current reading is higher than 97% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −161× | — |
| FY2024 | −4.8× | — |
| FY2023 | −1.6× | — |
| FY2022 | −5.8× | — |
| FY2021 | −39.3× | — |
| FY2020 | −17.1× | — |
| FY2019 | −5.5× | — |
| FY2018 | −14.3× | — |
| FY2017 | −93.2× | — |
| FY2016 | −30.7× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 67.4× | (82.03%) |
| Jun 2026 | 375× | — |
| Mar 2026 | −93.7× | — |
| Dec 2025 | −161× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MANE Veradermics Incorporated compare | −38.8× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −30.6× |
| DNTH Dianthus Therapeutics, Inc. compare | −23.4× |
| ERAS Erasca, Inc. compare | −16.6× |
| DFTX Definium Therapeutics, Inc. compare | −15.7× |
| COGT Cogent Biosciences, Inc. compare | −15.6× |
| EWTX Edgewise Therapeutics, Inc. compare | −15.5× |
| CRSP CRISPR Therapeutics AG compare | −8.3× |
| TVTX Travere Therapeutics, Inc. | 56.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement